β-lactam pharmacodynamics

Antimicrobial Pharmacodynamics in Theory and Clinical Practice, Second Edition

Volumn , Issue , 2007, Pages 129-146

  Tozuka, Zenzaburo ^a   Murakawa, Takeo ^b  

^a JCL Bioassay Corporation   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85015734280     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B influenzae. Br J Exp Pathol 1929; 10:226.
2. Abraham EP, Loder PB. Isolation of the cephalosporium sp. in Sardinia. In: Flynn EH, ed. Cephalosporins and Penicillins. Chemistry and Biology. New York & London: Academic Press, 1972:3-5.
3. Bodey GP, Ketchel SJ, Rodrigues N. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67:608-616.
4. Craig WA, Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 21:1-8.
5. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotics dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-292.
6. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36:2577-2583.
7. Dagan R, Abramason O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins. J Infect Dis 1997; 176:1253-1259.
8. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral cefaclor in treatment of acute otitis media in infant and young children. Antimicrob Agents Chemother 2000; 44:43-50.
9. Dangan R et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47:129-140.
10. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15:255-259.
11. Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to β -lactams. Antimicrob Agents Chemother 1993; 37:2045-2053.
12. Danziger LH, Pendland SL. Bacterial resistance to β -lactam antibiotics. Am J Health-Syst Pharm 1995; 52(suppl 2):S3-S8.
13. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on / -lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51-59.
14. Neuwirth C, Siebor E, Duez JM. Imipenem resistance in clinical isolates of Proteus mirabilis with alteration in penicillin-binding proteins. J Antimicrob Chemother 1995; 36:335-342.
15. Nikaido H. Prevention of drug access to bacterial targes: permeability barieres and actives efflux. Science 1994; 264:382-388.
16. Tozuka Z. Penicillins-parameters. In: Kuemmere HP, Murakawa T, Nightingale CH, eds. Pharmacokinetics of Antimicrobial Agents. Principle. Mthod. Application, Ecomed, Gmbh & Co.KG, 1993:65-67.
17. Tozuka Z. Cephalosporin-parameters. In: Kuemmere HP, Murakawa T, Nightingale CH, eds. Pharmacokinetics of Antimicrobial Agents. Principle. Mthod. Application, Ecomed, Gmbh & Co.KG 1993:93-98.
18. Murakawa T, Tozuka Z. Cephalosporins and other β-lactam antibiotics. In: Kuemmere HP, Murakawa T, Nightingale CH, eds. Pharmacokinetics of Antimicrobial Agents: Principle. Mthod. Application, Ecomed, Gmbh & Co.KG, 1993:69-86.
19. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291:1304-1351.
20. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res (NY) 1996; 13:963-977.
21. Hori R, Tomita Y, Katsura M, Inui K, Takano M. Transport of bestatin in rat renal brush-border membrane vesicles. Biochem Pharmacol 1993; 45:1763-1768.
22. Tsuji A, Terasaki T, Tamai I, Takeda K. In vivo evidence for carrier-mediated uptake of beta-lactam antibiotics through organic anion transport systems in rat kidney and liver. J Pharmacol Exp Ther 1990; 253:315-320.
23. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 1997; 272:18526-18529.
24. Jariyawat S, Sekine T, Takeda M, et al. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther 1999; 290:672-677.
25. Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, Endou H. Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int 1999; 56:2128-2136.
26. Sathirakul K, Suzuki H, Yasuda K, et al. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. J Pharmacol Exp Ther 1993; 265:1301-1312.
27. Vogelman B, Gudmundsson S, Leggett J, Tumidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158:831-847.
28. Frimodt-Moller, Bentzon MW, Thomsen VF. Experimental infection with Streptococcus pneu-moniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis 1986; 154:511-517.
29. Gerber AU, Brugger H-P, Fell C, Stritzko T, Stadler B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics J Infect Dis 1986; 153:90-97.
30. Roosendaal R, Bakker-Woudenbert IA, van den Berghe-van Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986; 30:403-408.
31. McCarthy CG, Finland M. Absorption and excretion of four penicillins, penicillin G, penicillin V, phenethicillin and phenylmercaptomethyl penicillin. New Engl J Med 1960; 263 (7):315-326.
32. Daschner FD et al. Ticarcillin concentration in serum, muscle and fat after a single intravenous injection. Antimicrob Ag Chemother 1980; 738-739.
33. Bunn PA, Phenoxymethyl Penicillin (V): pharmacologic observations. I Lab Clin Med 1956; 48(3):392-398.
34. Knudsen ET, Rolingson GN. Absorption and excretion of the potassium salt of 6(alpha-phenoxypropionamido)penicillanic acid. Lancet 1959; 1105-1109.
35. Bond JM, Lightbrown JW, Barber M, Waterworth PM, A comparison of four phenoxypenicillin. Med J 1;2(5363):956-961 p63.
36. Phlipson A, Sabath LD, Rosner B. Sequence effect on ampicillin blood levels noted in an amoxicillin, ampicillin and epicillin triple crossover study. Antimicrob Ag Chemother 1975; 3:311-320.
37. Rotholt K, Nielsen B, Kristensen E. Clinical pharmacology of Pivampicillin. 1974; 6:563-571.
38. Knudsen ET, Rolinson GN. Absorption and excretion of Penbritin. Br Med J 1961; 2:198-200.
39. Eshelman FN, Spyker DA. Pharmacokinetic of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob AG Chemother 1978; 14:539-543.
40. Kunst MW, Mattie H. Absorption of pivampicillin in postoperative patients. Antimicrob AG Chemother 1975; 8:11-14.
41. Brown RM et al. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother 1982; 21(4):738-739.
42. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacoki-netics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intraabdominal infection. J Antimicrob Chemother 2005; 56:388-395.
43. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003; 23:291-295.
44. Tod M, Minozzi C, Beaucaire G, Ponsonnet D, Cougnard J, Petitjean O. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-phar-macodynamic study. J Antimicrob Chemother 1999; 44:99-108.
45. Sakurai Y, Hishikawa T, Hiramatsu N, et al. Pharmacokinetic analysis of cefozopran in neonatal infections-population pharmacokinetics using nonmem. Jpn J Antibiot 1999; 52:16-23.
46. Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother 2005; 49: 2760-2766.
47. Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. J Antimicrob Chemother 2001; 47:51-59.
48. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacoki-netics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004; 48:1159-1167.
49. Dailly E, Kergueris MF, Pannier M, Jolliet P, Bourin M. Population pharmacokinetics of imipenem in burn patients. Fundam Clin Pharmacol 2003; 17:645-650.
50. Dailly E, Pannier M, Jolliet P, Bourin M. Population pharmacokinetics of ceftazidime in burn patients. Br J Clin Pharmacol 2003; 56:629-634.
51. Mouton JW, Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38:931-936.
52. Cappelletty DM, Kang SL, Palmer SM, Rybak MJ. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 1995; 33:1797-1801.
53. Mordenti JJ, Quintiliani R, Nightingale CH. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother 1985; 15:313-321.
54. Livingston DH, Wang MT. Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock. Am J Surg 1993; 165:203-207.
55. Gerber AU. Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections. Scand J Infect Dis 1991; (suppl 74):147-154.
56. Bakker-Woudenberg IA, van den Berg JC, Fontijne P, Michel MF. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol 1984; 3:131-135.
57. Totsuka K, Shimizu K, Leggett J, Vogelman B, Craig WA. Correlation between the pharma-cokinetic parameters and the efficacy of combination therapy with an aminoglycoside and a β -lactam.
58. Ueda Y ed. Proceedings of the International Symposium on Netilmicin. Professional Postgraduate Services, Japan, 1985:41-48.
59. Nicolau DP, McNabb JC, Lacy MK, Li J, Quintiliani R, Nightingale CH. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. In press.
60. Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996; 40:61-64.
61. Daenen S, Erjavec Z, Uges DRA, Vries HG-Hospers, Jonge P, Halie MR. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995; 14:188-192.
62. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996; 40:691-695.
63. Lagast H, Meunier F-Carpenter, Klastersky J. Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol 1983; 2:554-558.
64. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67:608-611.
65. Zeisler JA, McCarthy JD, Richelieu WA, Nichol MB. Cefuroxime by continuous infusion: a new standard of care? Infect Med 1992; 9:54-60.
66. Ambrose PG, Quintiliani R, Nightingale CH, Nicolau DP. Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. Infect Dis Clin Prac 1998; 7:463-470.
67. Woodnutt Berry V, Mizen L. Effect of protein binding on penetration of β -lactams into rabbit peripheral lymph. Antimicrob Agents Chemother 1995; 39:2678-2683.
68. Ryan DM, Hodges B, Spencer GR, Harding SM. Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular nuid. Antimicrob Agents Chemother 1982; 22:995-998.
69. Kalager T, Digranes A, Bergan T, Solberg CO. The pharmacokinetics of ceftriaxone in serum, skin blister and thread nuid. J Antimicrob Chemother 1984; 13:479-485.
70. Tozuka, Z. Isolation and identification of decomposed products of cefixime with gastrointestinal contents or feces. Internal Report CRR860144 in Fujisawa Pharmaceutical Co. Ltd., J Mass Spectrom 2003; 38:793-808.
71. FDA Guidance 2005, Pharmacogenomics data submission.
72. FDA Guidance 2005, Safety testing of drug metabolites.
73. EMEA Position paper on non-clinical safety studies to support clinical trials with a singledose microdose.
74. FDA Guidance 2006, Exploratory IND study.
75. Ke W, Bethel CR, Thomson JM, Bonomo RA, Akker FV. Crystal structure of KPC-2: Insights into carbapenemase activity in class A beta-lactamases. Biochemistry 2007 Apr 19.
76. Brewin A, Arango L, Hadley WK, Murray JF. High-dose penicillin therapy and pneumococcal pneumonia. JAMA 1974; 230:409A13.